Netherlands-incorporated Mylan (Nasdaq: MYL) on Friday announced that it will launch two new HIV treatments, Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) and Cimduo (efavirenz/lamivudine/tenofovir disoproxil fumarate).
Mylan anticipates introducing Symfi Loand Cimduo, both approved by the Food and Drug Administration last month, in the second quarter of this year.
These upcoming launches will extend Mylan's global antiretroviral (ARV) platform and help address the high cost of HIV treatment in the USA. Total spending for HIV medications in the USA exceeds $20 billion annually, and HIV is a top cost driver for many healthcare payers, such as Medicaid, the company said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze